The Coca-Cola Co K vs Nuwellis Inc — how do they compare? The Coca-Cola Co K trades at $88.05 (market cap $377.63B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: The Coca-Cola Co K is far larger — about 171650× Nuwellis Inc's market cap, and The Coca-Cola Co K pays a 2.42% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Nuwellis Inc for 26 Days on average.
| KO | NUWE | |
|---|---|---|
Market Cap | $377.63B | $2.20M |
Volume | 14,894,568 | 121,544 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $146.65 |
52-Week Low | $66.37 | $0.68 |
Typical Hold Time | 154 Days | 26 Days |
Enterprise Value | $404.81B | -$1.52M |
Dividend Yield | 2.42% | — |
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $87.77, up 2.27% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, 28.56% net margin, and 44.23% ROE. Recent institutional buying activity and positive analyst sentiment (60% buy ratings) support the stock's upward trajectory. KO maintains its dividend aristocrat status with 64 consecutive years of dividend increases, paying $0.53 per share in the upcoming H2-26 distribution.
KO presents a compelling investment case with stable revenue growth, exceptional profitability, and strong institutional support. The stock trades at a premium valuation (P/E 26.36) but justifies it with consistent execution. Key risks include regional demand divergence in Asia and elevated debt levels. With a consensus price target of $95.75 offering 9% upside potential, KO remains a quality defensive holding for dividend-focused investors seeking stable returns.
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →